CANNABICS PHARMACEUTICALS INC.: Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has entered into agreement with Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases. Read More »

DIAGNOSTIC SOLUTIONS LABORATORY: Revolutionizes Precision Medicine with GenomicInsight™ Genomic Health Profile Powered by Opus23 Explorer™

Diagnostic Solutions Laboratory (DSL) continues its innovative vision to transform and improve personalized medicine by introducing its first DNA SNP test, GenomicInsight™ Genomic Health Profile powered by Opus23 Explorer™, a proprietary version of DataPunk's Opus23 informatics software, conceived, developed, and coded by Dr. Peter D'Adamo, Distinguished Professor of Clinical Sciences, University of Bridgeport. Read More »

DAIICHI SANKYO INC.: Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet

Daiichi Sankyo Europe (hereafter, Daiichi Sankyo) and Esperion Therapeutics Inc. (hereafter, Esperion) announced today the validation of the Marketing Authorisation Application (MAA) for bempedoic acid and the bempedoic acid / ezetimibe fixed dose combination tablet by the European Medicines Agency (EMA) Read More »